CD276 and cancer: Inspired by the DNA damage-inducing capability of cmLumiOpto, we hypothesize that combining the cancer mitochondria-targeted cmLumiOpto, delivered via CD276 mAb-Exo-AAV, with PARPi will lead to a synergistic effect.